tradmap

ADVB Earnings Advanced Biomed Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing

Annual results

Diluted EPS (annual)
-$3 $1 $5 $0 2024 2025 2026
EPS
Revenue (annual)
$0 $63819 $127637 2024 2025 2026
Revenue
Net income (annual)
-$3M $2M $7M $0 2024 2025 2026
Net income

Quarterly results

Diluted EPS (quarterly)
-$1 $2 $6 $0 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26 Q3 '26 Q4 '26
EPS
Net income (quarterly)
-$1M $3M $7M $0 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26
Net income
Return on equity (quarterly)
-147% 33% 212% 0% Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26
ROE

Reported EPS history

1–13 of 13
Q4 2026 (derived)2026-06-30-0.092026-10-1310-K
FY 20262026-06-305.332026-10-1310-K
Q3 20262026-03-31-0.382026-05-1510-Q
Q2 20262025-12-316.202026-02-1310-Q
Q1 20262025-09-30-0.402025-11-1910-Q
Q4 2025 (derived)2025-06-30-0.632025-10-0810-K
FY 20252025-06-30-3.182025-10-0810-K
Q3 20252025-03-31-1.352025-05-1510-Q
Q2 20252024-12-31-1.002025-04-1510-Q
Q1 20252024-09-30-0.20——
FY 20242024-06-30-2.80——
Q3 20242024-03-31-1.00——
Q2 20242023-12-31-0.20——

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.